- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01499368
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
August 28, 2020 updated by: Boryung Pharmaceutical Co., Ltd
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
495
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification
Exclusion Criteria:
- Gastric or duodenal ulcers (excluding ulcer scars)
- Concurrent presence of Barrett's esophagus
- A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks
- Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lafutidine
Lafutidine 20mg/day
|
Lafutidine 20mg/day
|
Active Comparator: Famotidine
Famotidine 40mg/day
|
Famotidine 40mg/day
|
Other: Omeprazole
Omeprazole 20mg/day
|
Omeprazole 20mg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovery Rates of Reflux Esophagitis
Time Frame: 8 weeks
|
Recovery rates of reflux esophagitis on the Esophago Gastro Duodenoscopy test after 8 week treatment-FAS
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Proportion of Days Without 'Cardinal Symptom'
Time Frame: 4 or 8 week
|
The proportion of days without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sesation in the chest, Acid reflux, Heartburn including chest pain
|
4 or 8 week
|
The Proportion of Daytimes Without 'Cardinal Symptom'
Time Frame: 4 or 8 week
|
The proportion of daytimes without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain
|
4 or 8 week
|
The Proportion of Nighttimes Without 'Cardinal Symptom'
Time Frame: 4 or 8 week
|
The proportion of Nighttimes without 'Cardinal symptom' after 4 or 8 treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain
|
4 or 8 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Sang Woo Lee, Korea University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
December 21, 2011
First Submitted That Met QC Criteria
December 22, 2011
First Posted (Estimate)
December 26, 2011
Study Record Updates
Last Update Posted (Actual)
September 16, 2020
Last Update Submitted That Met QC Criteria
August 28, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Esophageal Diseases
- Esophagitis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Histamine Antagonists
- Histamine Agents
- Histamine H2 Antagonists
- Famotidine
- Omeprazole
- Lafutidine
Other Study ID Numbers
- LAF-BR-CT-302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erosive Esophagitis
-
Braintree LaboratoriesRecruitingErosive EsophagitisUnited States
-
Phathom Pharmaceuticals, Inc.CompletedErosive EsophagitisUnited States, Poland, Bulgaria, United Kingdom, Czechia, Hungary
-
Daewoong Pharmaceutical Co. LTD.Hanyang UniversityUnknownErosive EsophagitisKorea, Republic of
-
TakedaCompletedEfficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive EsophagitisErosive EsophagitisChina, Taiwan, Korea, Republic of, Malaysia
-
Onconic Therapeutics Inc.RecruitingErosive EsophagitisKorea, Republic of
-
AstraZenecaLaboratory Corporation of America; Medidata Solutions; IQVIA RDS Inc.; Calyx; Thermo... and other collaboratorsRecruitingErosive EsophagitisUnited States, Italy, Belgium, Vietnam, Spain, Portugal, Russian Federation, Argentina, Greece, Australia, Lithuania
-
Konkuk University Medical CenterDaewoong Pharmaceutical Co. LTD.RecruitingErosive EsophagitisKorea, Republic of
-
Cinclus Pharma AGParexelCompletedErosive EsophagitisPoland, Bulgaria, Serbia, Georgia, United States, Czechia, Hungary, Ukraine
-
HK inno.N CorporationCompletedErosive EsophagitisKorea, Republic of
-
HK inno.N CorporationCompletedErosive EsophagitisKorea, Republic of
Clinical Trials on Lafutidine
-
Wuhan Union Hospital, ChinaCompleted
-
Taiho Pharmaceutical Co., Ltd.UCB PharmaCompletedGastroesophageal RefluxJapan
-
King Saud UniversityCompletedPulmonary Aspiration of Gastric Contents
-
Boryung Pharmaceutical Co., LtdCompletedGastric UlcerKorea, Republic of
-
Boryung Pharmaceutical Co., LtdThe Catholic University of KoreaCompletedPeptic UlcerKorea, Republic of
-
Canadian Network for Observational Drug Effect...Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...CompletedGastroesophageal Reflux Disease (GERD) | Community-acquired PneumoniaCanada